Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome
| Autor: | Ako Fukami, Sachiko Nakamura, Hisashi Adachi, Yoko Umeki, Yuji Hirai, Erika Nakao, Yume Nohara, Yoshihiro Fukumoto, Aya Obuchi, Ayako Yoshimura, Mika Enomoto, Kyoko Ohbu-Murayama |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
business.industry Endocrinology Diabetes and Metabolism Insulin resistance Articles General Medicine Ezetimibe medicine.disease Metabolic syndrome Intestinal absorption Endocrinology Blood pressure Seven Countries Study Internal medicine Diabetes mellitus Internal Medicine medicine business Body mass index medicine.drug |
| Zdroj: | Journal of Diabetes Investigation |
| ISSN: | 2040-1124 2040-1116 |
| DOI: | 10.1111/jdi.12298 |
| Popis: | Aims/Introduction Ezetimibe lowers serum lipid levels by inhibiting intestinal absorption of dietary and biliary cholesterol. However, the effect of ezetimibe on insulin resistance remains unclear. The aim of the present study was to examine this issue in patients with metabolic syndrome in local-dwelling Japanese, who were not being treated with lipid-lowering drugs. Materials and Methods In 2009, 1,943 participants received a health examination in the Tanushimaru Study, a Japanese cohort of the Seven Countries Study, of whom 490 participants had metabolic syndrome. Among them, 61 participants (41 men and 20 women) were examined in the present study. They were treated with 10 mg of ezetimibe once a day for 24 weeks, combined with standard diet and exercise therapy. Results Bodyweight (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|